Singapore markets open in 5 hours 38 minutes

Ocugen, Inc. (OCGN)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
2.0200+0.2000 (+10.99%)
As of 03:22PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close1.8200
Open2.0700
Bid2.0000 x 21500
Ask2.0100 x 3200
Day's range1.8500 - 2.0888
52-week range1.6700 - 17.6500
Volume8,899,321
Avg. volume5,212,395
Market cap437.463M
Beta (5Y monthly)4.22
PE ratio (TTM)N/A
EPS (TTM)-0.3470
Earnings date07 Nov 2022 - 11 Nov 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est7.00
  • Motley Fool

    Why Ocugen Stock Topped the Market Today

    Although it hasn't been the most popular coronavirus stock, Ocugen (NASDAQ: OCGN) clearly found some new fans on Thursday. In a one-two punch, Ocugen has appointed a new chief medical officer and chief scientific officer. The former is Robert Hopkins, a physician with over 20 years in both the public and private sectors of the healthcare industry.

  • Motley Fool

    Why Ocugen Stock Is Racing Higher Today

    Shares of clinical-stage biotech Ocugen (NASDAQ: OCGN) are on fire today. Mizuho's analyst noted that Ocugen's shares are only currently being valued at the commercial potential of its COVID-19 vaccine known as Covaxin. Ocugen is co-commercializing the vaccine in North America with its developer Bharat Biotech of India.

  • Motley Fool

    Here's How This Beaten-Down Stock Could 10X by 2024

    On that note, Ocugen (NASDAQ: OCGN) stock is down by more than 65% this year as the small biotech has struggled to commercialize a coronavirus vaccine. To remedy that issue, it's licensing a coronavirus vaccine called Covaxin from Bharat Biotech, an Indian pharmaceutical business. While it's already approved in India, the chances of Ocugen successfully commercializing Covaxin in the U.S. remain a question mark.